{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01399749",
      "OrgStudyIdInfo": {
        "OrgStudyId": "HLPTRA-2009-01"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2009-016628-29",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects",
      "OfficialTitle": "A Comparative Clinical Trial for the Repair of Chondral Knee Defects: Transplantation of Autologous Cultured Chondrocytes vs. Autologous Mesenchymal Stem Cells Derived From Adipose Tissue",
      "Acronym": "ASCROD"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2011",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2012",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2012",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 20, 2011",
      "StudyFirstSubmitQCDate": "July 21, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 22, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 21, 2011",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 22, 2011",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Alonso C. Moreno Garcia",
        "ResponsiblePartyOldOrganization": "La Paz University Hospital. Orthopedic Surgery and Traumatology Department"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The objective of our study is to compare the safety and effectiveness of the use of autologous cultured adipose tissue-derived stem cells versus cultured autologous chondrocytes for the treatment of chondral knee lesions.",
      "DetailedDescription": "Chondral knee lesions are frequent and produce important functional limitations and arthrosis development. Arthrosis is one of the most important causes of disability and its treatment with prosthetic surgery is associated with a high cost, and is not free of other complications. Several studies of cell therapy with autologous chondrocytes have shown efficacy in the treatment of this type of lesions, and currently is a common technique for the treatment of focal lesions of articular cartilage. Autologous chondrocyte transplant is associated with morbidity of the cartilage sample removal, which needs intra-articular surgery, and the limited tissue sample for culture. Adipose tissue-derived mesenchymal stem cells (ASC) have demonstrated chondrocytic differentiation and have been used in animal models for articular cartilage repair. Adipose tissue yields more ASC than chondrocytes are obtained from cartilage, and liposuction is simple and with less adverse events than arthroscopy. It is worth mentioned that culture conditions are less stringent for ASC than for chondrocytes, in terms of number of passages to obtain the amount of cells needed for implantation.\n\nWe propose a randomized clinical trial, in which we compare the surgical implantation of either autologous chondrocytes or autologous ASC to treat chondral knee lesions."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Articular Cartilage Lesion of the Femoral Condyle"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Cartilage",
          "Articular",
          "Femoral",
          "Knee",
          "Chondrocytes",
          "Adipose tissue-derived mesenchymal stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous ASC implantation",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Treatment with autologous ASC",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Implantation of autologous cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Autologous Chondrocytes implantation",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Treatment with autologous chondrocytes",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Implantation of autologous cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "Implantation of autologous cells",
            "InterventionDescription": "Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous ASC implantation",
                "Autologous Chondrocytes implantation"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "ACI"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Hyaline cartilage production for chondral knee lesions repair",
            "PrimaryOutcomeTimeFrame": "18 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Efficacy: Clinical evolution",
            "SecondaryOutcomeDescription": "Changes in Clinical tests and SF-12 Health Survey over 18 months",
            "SecondaryOutcomeTimeFrame": "18 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Functional evolution",
            "SecondaryOutcomeDescription": "Changes in Western Ontario-McMaster Osteoarthritis Score(WOMAC) over 18 months",
            "SecondaryOutcomeTimeFrame": "18 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Functional evolution",
            "SecondaryOutcomeDescription": "Changes in Knee Society Score(KSS) over 18 months",
            "SecondaryOutcomeTimeFrame": "18 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Histological evaluation",
            "SecondaryOutcomeDescription": "Hyaline cartilage production by histological methods at 18 months",
            "SecondaryOutcomeTimeFrame": "18 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Radiological evaluation",
            "SecondaryOutcomeDescription": "MRI at 18 months",
            "SecondaryOutcomeTimeFrame": "18 months"
          },
          {
            "SecondaryOutcomeMeasure": "Safety: Adverse events",
            "SecondaryOutcomeDescription": "Sistemic and local AEs especially attributable to implanted cells",
            "SecondaryOutcomeTimeFrame": "18 months"
          },
          {
            "SecondaryOutcomeMeasure": "Safety: Acute inflammatory events",
            "SecondaryOutcomeDescription": "Increase of pain of at least 30 mm on a 100 mm visual analog scale (VAS) along with self-reported swelling within 3 days post-cell application",
            "SecondaryOutcomeTimeFrame": "18 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSymptomatic focal articular cartilage lesion on the medial femoral condyle\nLesion on femoral condyle between 1 and 5 cm²\nICRS Grade III/IV\nStable knee\nSigned patient informed consent\n\nExclusion Criteria:\n\nClinically relevant member malalignment (> 5 degrees)\nNon stable knee\nInflammatory joint disease\nKnee surgery in the last year (transplant, suture or resection of the meniscus, mosaicplasty, microfracture)\nParticipation in concurrent trials or in the previous 3 months\nSubjects with hepatitis, HIV or syphilis\nMalignancy in the previous 5 years\nAlcohol and/or drug abuse\nPoor general health as judged by Investigator\nClinically relevant second cartilage lesion on the patella\nPatellofemoral cartilage lesion\nKnown allergy to gentamicin or penicillins (or presence of multiple severe allergies)\nHaving received hyaluronic acid intra-articular injections in the affected knee within the last 6 months of baseline\nTaking specific OA drugs such as chondroitin sulfate, diacerein, n-glucosamine, piascledine, capsaicin within 2 weeks of the baseline visit\nCorticosteroid treatment by systemic or intra-articular route within the last month of baseline or intramuscular or oral corticosteroids within the last 2 weeks of baseline\nChronic use of anticoagulants\nUncontrolled diabetes\nAny concomitant painful or disabling disease of the spine,hips or lower limbs that would interfere with evaluation of the afflicted knee\nAny clinically significant or symptomatic vascular or neurologic disorder of the lower extremities\nLiver enzymes (SGOT, SGPT, Alkaline Phosphatase) of more then two times the upper limit of normal or any other result that is clinically important according to the Investigator\nCRP > 10 mg/l",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "55 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Alonso C. Moreno Garcia, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+34 917277314",
            "CentralContactEMail": "alonso.moreno.garcia@gmail.com"
          },
          {
            "CentralContactName": "Fernando de Miguel",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+34 912071022",
            "CentralContactEMail": "fdemiguel.hulp@salud.madrid.org"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Alonso C. Moreno Garcia, MD",
            "OverallOfficialAffiliation": "Orthopedic Surgery and Traumatology Department. Knee Unit",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "La Paz University Hospital. Orthopedic Surgery and Traumatology Department, Knee Unit; Cell Therapy Laboratory.",
            "LocationCity": "Madrid",
            "LocationZip": "28046",
            "LocationCountry": "Spain",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Alonso C. Moreno Garcia, MD",
                  "LocationContactRole": "Principal Investigator"
                },
                {
                  "LocationContactName": "Jose L. Leal Helmling, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Santiago Bello, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Fernando de Miguel, PhD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Damian Garcia-Olmo, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Mariano A. Garcia-Arranz, PhD",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "8078550",
            "ReferenceType": "background",
            "ReferenceCitation": "Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994 Oct 6;331(14):889-95."
          },
          {
            "ReferencePMID": "11869080",
            "ReferenceType": "background",
            "ReferenceCitation": "Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002 Mar;10(3):199-206."
          },
          {
            "ReferencePMID": "20831449",
            "ReferenceType": "background",
            "ReferenceCitation": "García-Gómez I, Elvira G, Zapata AG, Lamana ML, Ramírez M, Castro JG, Arranz MG, Vicente A, Bueren J, García-Olmo D. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther. 2010 Oct;10(10):1453-68. doi: 10.1517/14712598.2010.519333. Review."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    }
  }
}